No Major Effect of Innate Immune Genetics on Acute Kidney Rejection in the First 2 Weeks Post-Transplantation.
IL6 -6331
acute rejection
immune genetics
kidney transplantation
tacrolimus
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2019
2019
Historique:
received:
14
10
2019
accepted:
24
12
2019
entrez:
11
3
2020
pubmed:
11
3
2020
medline:
11
3
2020
Statut:
epublish
Résumé
Innate immunity contributes to acute rejection after kidney transplantation. Genetic polymorphisms affecting innate immunity may therefore influence patients' risk of rejection. To investigate the effect of recipient and donor This study included 154 kidney transplant recipients and 81 donors successfully genotyped for 17 polymorphisms in these genes. All recipients were under triple immunosuppressant therapy of TAC, mycophenolate mofetil, and prednisolone. Recipient and donor genotype differences in acute rejection incidence within the first 2 weeks post-transplantation were assessed by logistic regression, adjusting for induction therapy, human leukocyte antigen mismatches, kidney transplant number, living donor, and peak panel-reactive antibody scores. A trend (Cochran-Armitage P = 0.031) of increasing acute rejection incidence was observed from recipient This study did not detect any statistically significant effects of recipient or donor innate immune genetics on acute rejection incidence in the first 2 weeks post-transplantation. However, the sample size was small, and future larger studies or meta-analyses are required to demonstrate conclusively if innate immune genetics such as
Sections du résumé
BACKGROUND
BACKGROUND
Innate immunity contributes to acute rejection after kidney transplantation. Genetic polymorphisms affecting innate immunity may therefore influence patients' risk of rejection.
OBJECTIVE
OBJECTIVE
To investigate the effect of recipient and donor
METHODS
METHODS
This study included 154 kidney transplant recipients and 81 donors successfully genotyped for 17 polymorphisms in these genes. All recipients were under triple immunosuppressant therapy of TAC, mycophenolate mofetil, and prednisolone. Recipient and donor genotype differences in acute rejection incidence within the first 2 weeks post-transplantation were assessed by logistic regression, adjusting for induction therapy, human leukocyte antigen mismatches, kidney transplant number, living donor, and peak panel-reactive antibody scores.
RESULTS
RESULTS
A trend (Cochran-Armitage P = 0.031) of increasing acute rejection incidence was observed from recipient
CONCLUSIONS
CONCLUSIONS
This study did not detect any statistically significant effects of recipient or donor innate immune genetics on acute rejection incidence in the first 2 weeks post-transplantation. However, the sample size was small, and future larger studies or meta-analyses are required to demonstrate conclusively if innate immune genetics such as
Identifiants
pubmed: 32153387
doi: 10.3389/fphar.2019.01686
pmc: PMC7045476
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1686Informations de copyright
Copyright © 2020 Hu, Barratt, Coller, Sallustio and Somogyi.
Références
Eur J Immunogenet. 1997 Feb;24(1):1-8
pubmed: 9043871
Transplantation. 2015 May;99(5):1043-50
pubmed: 25539466
Kidney Int. 2005 Jun;67(6):2454-61
pubmed: 15882292
Transplantation. 1998 Oct 27;66(8):1014-20
pubmed: 9808485
Cancer Res. 2003 May 15;63(10):2610-5
pubmed: 12750287
Clin Transplant. 2006 Jan-Feb;20(1):30-6
pubmed: 16556150
Gene. 2016 Apr 25;581(1):57-65
pubmed: 26794449
Transpl Immunol. 2012 Jan;26(1):11-8
pubmed: 22024650
Mol Cell Biochem. 2008 Apr;311(1-2):57-65
pubmed: 18165865
Clin Transplant. 2012 Jul-Aug;26(4):E428-37
pubmed: 22672477
Transplant Proc. 2012 Jun;44(5):1241-9
pubmed: 22663993
Transplant Proc. 2015 Jul-Aug;47(6):1746-53
pubmed: 26293045
Transplantation. 2001 Feb 15;71(3):469-76
pubmed: 11233912
Pain. 2016 Nov;157(11):2458-2466
pubmed: 27649267
Support Care Cancer. 2015 May;23(5):1233-6
pubmed: 25318697
J Immunol Res. 2016;2016:2697860
pubmed: 28058265
Brain. 2008 Apr;131(Pt 4):1069-77
pubmed: 18304957
PLoS One. 2015 Sep 02;10(9):e0137179
pubmed: 26332828
BMC Med Genet. 2009 Jul 22;10:73
pubmed: 19624831
Am J Transplant. 2007 May;7(5):1201-8
pubmed: 17359502
Nature. 1992 Apr 30;356(6372):768-74
pubmed: 1574116
Eur J Clin Pharmacol. 2013 Mar;69(3):431-8
pubmed: 22960943
Biochim Biophys Acta. 2011 May;1813(5):878-88
pubmed: 21296109
Immunol Today. 1980 Dec;1(6):113-7
pubmed: 25290353
Transpl Immunol. 2011 Jul;25(1):61-71
pubmed: 21586325
Genes Immun. 2004 Sep;5(6):513-6
pubmed: 15306846
PLoS One. 2015 Jun 02;10(6):e0127540
pubmed: 26035439
Transplantation. 2017 Feb;101 Suppl 2S:S1-S41
pubmed: 28125449
Immunity. 2004 Feb;20(2):121-31
pubmed: 14975235
J Am Soc Nephrol. 2014 Jul;25(7):1387-400
pubmed: 24762401
Transplant Proc. 2007 Mar;39(2):412-4
pubmed: 17362744
Cytokine. 2014 Nov;70(1):11-20
pubmed: 24986424
Br J Clin Pharmacol. 2019 Sep;85(9):2170-2175
pubmed: 31219197
Am J Transplant. 2008 Apr;8(4):753-60
pubmed: 18294345
Hum Genet. 2011 Oct;130(4):547-61
pubmed: 21424379
Pharmacogenet Genomics. 2019 Jan;29(1):9-17
pubmed: 30489455
Ther Drug Monit. 2019 Aug;41(4):528-532
pubmed: 31259882
Int J Infect Dis. 2013 Dec;17(12):e1092-7
pubmed: 23906542
Transplantation. 2000 Nov 27;70(10):1485-91
pubmed: 11118095
Clin Chem. 2008 May;54(5):841-50
pubmed: 18356242
N Engl J Med. 2010 Oct 7;363(15):1451-62
pubmed: 20925547
Basic Clin Pharmacol Toxicol. 2018 Sep;123(3):320-326
pubmed: 29603629
N Engl J Med. 1994 Oct 27;331(17):1110-5
pubmed: 7523946
Clin Transplant. 2010 Jan-Feb;24(1):40-7
pubmed: 19236436
J Antibiot (Tokyo). 1987 Sep;40(9):1249-55
pubmed: 2445721
Nat Rev Immunol. 2005 Jun;5(6):446-58
pubmed: 15928677
Transplantation. 2001 Oct 27;72(8):1444-50
pubmed: 11685118
J Mol Neurosci. 2014 Apr;52(4):497-506
pubmed: 24352713
Med Sci Monit. 2016 Dec 03;22:4736-4741
pubmed: 27913812
Nat Rev Immunol. 2002 Oct;2(10):725-34
pubmed: 12360211
J Immunol. 2008 Feb 1;180(3):1903-12
pubmed: 18209088
Proc Natl Acad Sci U S A. 1989 Jul;86(14):5227-31
pubmed: 2787508
Hum Mol Genet. 1999 Jan;8(1):93-7
pubmed: 9887336
J Clin Invest. 1998 Oct 1;102(7):1369-76
pubmed: 9769329
Arthritis Rheum. 2004 Jun;50(6):1976-83
pubmed: 15188375
Ren Fail. 2016;38(1):57-64
pubmed: 26524497
Mol Immunol. 1997 Apr;34(5):391-9
pubmed: 9293772